FDA Waves Safety Flag as Arcalyst Heads to Adcomm
By Mari Serebrov
Monday, May 7, 2012
WASHINGTON – Regeneron Pharmaceuticals Inc. is hoping Arcalyst can do what another IL-1 blocker couldn't do last year – wow the Arthritis Advisory Committee (AAC).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.